Events

Elrig Drug Discovery Digital w/ Amparo Toboso-Navasa

Endotype-driven target identification detection using omics data

Sam Abujudeh, Marika Catapano, Paidi Creed, Jaime Domingues, Craig Glastonbury, Josep Montserrat,  Francesca Mulas, Povilas Norvaisas, Delphine Rolando, Aaron Sim, Amparo Toboso-Navasa, Hamish Tomlinson, Arpad Vezer.


Cancer, sarcopenia, diabetes, and ALS, are but a few diseases that present notable heterogeneity between patients in both symptoms and aetiology. This heterogeneity extends to the patients’ response to experimental treatments, therefore presenting a significant challenge for drug discovery.

Embracing this challenge, at BenevolentAI we have developed an approach using omics data to identify patient subgroups. Here we present this approach, illustrated with a case study from our patient stratification drug discovery programs.

Unsupervised machine learning methods can be used to identify subgroup-specific patterns; the biological interpretation of these patterns is key for the identification of endotype-specific disease-modifying targets. We have developed a systematic evaluation of the identified patterns by assessing confounding variables, clinical covariates and biological mechanisms.  Therefore, biologically meaningful subgroup-specific patterns are defined by the lack of confounding effects, their correlation with clinical variables and their implication in biological pathways. 

Our pipeline tackles the challenges of interpreting subgroup-specific patterns derived from high-dimensional omics data, while uncovering pathobiological aspects of the disease specific to a group of patients. The identification of biological mechanisms that explain a given disease in different patient subgroups will facilitate drug discovery by providing targets regulating those mechanisms.


Amparo Toboso-Navasa

Drug Discovery Scientist

At BenevolentAI, Drug Discovery Scientists with Biology, Pharmacology and Chemistry backgrounds, work together with Bioinformaticians and AI Scientists.  With our joint effort,  we focus on identifying heterogeneous diseases that will benefit from our Precision Medicine approach. We look for omics datasets that reflect this heterogeneity while capturing clinical information; this will allow our models to find patient subgroups. Then, Drug Discovery Scientists, as myself, interpret the underlying biology to find disease drivers in each endotype. Target identification is followed by target validation in experimental settings that mimic the characteristics of each patient subpopulation so we find the right target for the right patient. 



More Posts

You Might Also Like

News
Rob Quinn to join BenevolentAI as Chief Financial Officer
Rob Quinn to join BenevolentAI as Chief Financial Officer to guide the company's growth and financial direction.
Oct 21, 2020
Blog
Data Diversity: Ten practical approaches to acquiring the right datasets Part 1
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
Blog
Data Diversity: Ten practical approaches to acquire the right datasets Part 2
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
News
NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial
Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
Oct 9, 2020
News
BenevolentAI welcomes Professor Russ Altman as scientific advisor
As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.
Oct 1, 2020
Blog
The Diversity Analysis Tool: Towards better Diversity in Data for Precision Medicine
As part of the data diversity initiative, our team released a simple open-source programme to evaluate the diversity of datasets and inspire others to search for solutions to drive innovation that benefits everyone.
Sep 22, 2020